Cargando…

Towards Personalising the Use of Biologics in Rheumatoid Arthritis: A Discrete Choice Experiment

INTRODUCTION: There have been promising developments in technologies and associated algorithm-based prescribing (‘stratified approach’) to target biologics to sub-groups of people with rheumatoid arthritis (RA). The acceptability of using an algorithm-guided approach in practice is likely to depend...

Descripción completa

Detalles Bibliográficos
Autores principales: Vass, Caroline M, Barton, Anne, Payne, Katherine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8739310/
https://www.ncbi.nlm.nih.gov/pubmed/34142326
http://dx.doi.org/10.1007/s40271-021-00533-z
_version_ 1784629076701478912
author Vass, Caroline M
Barton, Anne
Payne, Katherine
author_facet Vass, Caroline M
Barton, Anne
Payne, Katherine
author_sort Vass, Caroline M
collection PubMed
description INTRODUCTION: There have been promising developments in technologies and associated algorithm-based prescribing (‘stratified approach’) to target biologics to sub-groups of people with rheumatoid arthritis (RA). The acceptability of using an algorithm-guided approach in practice is likely to depend on various factors. OBJECTIVE: This study quantified preferences for an algorithm-guided approach to prescribing biologics (termed ‘biologic calculator’). METHODS: An online discrete choice experiment (DCE) was designed to elicit preferences from patients and the public for using a ‘biologic calculator’ compared with conventional prescribing. Treatment approaches were described by five attributes: delay to starting treatment; positive and negative predictive value (PPV/NPV); risk of infection; and cost saving to the UK national health service. Each survey contained six choice sets asking respondents to select their preferred option from two hypothetical biologic calculators or conventional prescribing. Background questions included sociodemographics, health status and healthcare experiences. DCE data were analysed using mixed logit models. RESULTS: Completed choice data were collected from 292 respondents (151 patients with RA and 142 members of the public). PPV, NPV and risk of infection were the most highly valued attributes to respondents deciding between prescribing strategies. CONCLUSION: Respondents were generally receptive to personalised medicine in RA, but researchers developing personalised approaches should pay close attention to generating evidence on both the PPV and the NPV of their technologies. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40271-021-00533-z.
format Online
Article
Text
id pubmed-8739310
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-87393102022-01-20 Towards Personalising the Use of Biologics in Rheumatoid Arthritis: A Discrete Choice Experiment Vass, Caroline M Barton, Anne Payne, Katherine Patient Original Research Article INTRODUCTION: There have been promising developments in technologies and associated algorithm-based prescribing (‘stratified approach’) to target biologics to sub-groups of people with rheumatoid arthritis (RA). The acceptability of using an algorithm-guided approach in practice is likely to depend on various factors. OBJECTIVE: This study quantified preferences for an algorithm-guided approach to prescribing biologics (termed ‘biologic calculator’). METHODS: An online discrete choice experiment (DCE) was designed to elicit preferences from patients and the public for using a ‘biologic calculator’ compared with conventional prescribing. Treatment approaches were described by five attributes: delay to starting treatment; positive and negative predictive value (PPV/NPV); risk of infection; and cost saving to the UK national health service. Each survey contained six choice sets asking respondents to select their preferred option from two hypothetical biologic calculators or conventional prescribing. Background questions included sociodemographics, health status and healthcare experiences. DCE data were analysed using mixed logit models. RESULTS: Completed choice data were collected from 292 respondents (151 patients with RA and 142 members of the public). PPV, NPV and risk of infection were the most highly valued attributes to respondents deciding between prescribing strategies. CONCLUSION: Respondents were generally receptive to personalised medicine in RA, but researchers developing personalised approaches should pay close attention to generating evidence on both the PPV and the NPV of their technologies. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40271-021-00533-z. Springer International Publishing 2021-06-18 2022 /pmc/articles/PMC8739310/ /pubmed/34142326 http://dx.doi.org/10.1007/s40271-021-00533-z Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research Article
Vass, Caroline M
Barton, Anne
Payne, Katherine
Towards Personalising the Use of Biologics in Rheumatoid Arthritis: A Discrete Choice Experiment
title Towards Personalising the Use of Biologics in Rheumatoid Arthritis: A Discrete Choice Experiment
title_full Towards Personalising the Use of Biologics in Rheumatoid Arthritis: A Discrete Choice Experiment
title_fullStr Towards Personalising the Use of Biologics in Rheumatoid Arthritis: A Discrete Choice Experiment
title_full_unstemmed Towards Personalising the Use of Biologics in Rheumatoid Arthritis: A Discrete Choice Experiment
title_short Towards Personalising the Use of Biologics in Rheumatoid Arthritis: A Discrete Choice Experiment
title_sort towards personalising the use of biologics in rheumatoid arthritis: a discrete choice experiment
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8739310/
https://www.ncbi.nlm.nih.gov/pubmed/34142326
http://dx.doi.org/10.1007/s40271-021-00533-z
work_keys_str_mv AT vasscarolinem towardspersonalisingtheuseofbiologicsinrheumatoidarthritisadiscretechoiceexperiment
AT bartonanne towardspersonalisingtheuseofbiologicsinrheumatoidarthritisadiscretechoiceexperiment
AT paynekatherine towardspersonalisingtheuseofbiologicsinrheumatoidarthritisadiscretechoiceexperiment